Thu. 28 Mar 2024, 4:20pm ET
Benzinga
Earnings, News
INmune Bio (NASDAQ:INMB) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.44) by 6.82 percent. This is a 46.87 percent decrease over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $28.00 thousand which missed the analyst consensus estimate of $40.00 thousand by 30.00 percent. This is a 71.13 percent decrease over sales of $97.00 thousand the same period last year.